帯状疱疹治療薬市場：治療タイプ（抗ウイルス薬、抗炎症薬、その他）、投与経路（経口、局所）、流通チャネル（病院薬局、ドラッグストア・小売薬局、オンラインプロバイダー）別。世界の機会分析および産業予測、2021-2030年

Herpes Zoster Treatment Market by Treatment Type (Antiviral Medications, Anti Inflammatory Medications, and Others) Route Administration (Oral, and Topical) and Distribution Channel (Hospital Pharmacies, Drug Stores & Retail Pharmacies, and Online Providers): Global Opportunity Analysis and Industry Forecast, 2021-2030

帯状疱疹治療の世界市場は、2020年には2億1709万ドルで、2021年から2030年にかけてCAGR3.4%を記録し、2030年には3億342万ドルに達すると予測されています。帯状疱疹（帯状疱疹）は、水痘・帯状疱疹ウイルスによ... もっと見る

出版社	出版年月	電子版価格	ページ数	言語
Allied Market Research アライドマーケットリサーチ	2022年1月2日	US$6,168 シングルユーザーライセンスライセンス・価格情報注文方法はこちら	205	英語

サマリー

帯状疱疹治療の世界市場は、2020年には2億1709万ドルで、2021年から2030年にかけてCAGR3.4%を記録し、2030年には3億342万ドルに達すると予測されています。
帯状疱疹（帯状疱疹）は、水痘・帯状疱疹ウイルスによって引き起こされるウイルス感染症です。通常、背中、胸、顔などに水疱ができ、チカチカとした痛みと痒みを伴い、他の部位にも広がります。症状は通常、患部の皮膚分節に沿った痛みで始まり、2-3日後に拡大した小水疱性発疹が現れます。症状は、リンパ節、発熱、悪寒、頭痛、かゆみ、皮膚の盛り上がった点、その部分の発赤、皮膚の中や下に刺すような痛み、チクチク感、灼熱感、胃のむかつきなどです。帯状疱疹にかかる人は、水疱瘡の既往があり、多くの場合、数十年前にかかっています。この2つの症状は、水痘帯状疱疹と呼ばれる同じウイルスに由来しています。また、帯状疱疹にかかった人は、水痘にかかったことのない人に感染することがありますが、その人は帯状疱疹ではなく、水痘を発病することになります。帯状疱疹は、高齢者では免疫力が低下しているため、蔓延しています。放射線治療や化学療法を受けている人は、免疫力が低下しているため、帯状疱疹にかかりやすくなっています。
また、PCR法はVZVのDNAを迅速かつ高感度に検出することができ、現在では広く利用されています。帯状疱疹の検査後、内服薬や抗体などを用いた治療が行われます。抗ヒスタミン剤、減感作クリーム、ゲル、固定剤などを投与し、苦痛を軽減させる。帯状疱疹を発症するリスクの高い既往のある人には、ワクチンが投与されます。
帯状疱疹は、高齢者における水痘帯状疱疹ウイルスの再活性化により発生し、成人や子供と比較して、老年人口における帯状疱疹の発生率は高くなります。例えば、2021年、米国では、帯状疱疹のリスクは年齢とともに増加すると報告されています。米国では、高齢者の増加に伴い、帯状疱疹の発生率が増加することが予想されています。
また、老年人口の増加や帯状疱疹の増加も市場の成長に寄与しています。しかし、熟練した専門家の不足が市場成長の妨げになると予想されます。逆に、薬剤開発の増加は、市場に有利な成長機会を提供します。
帯状疱疹治療の世界市場は、治療タイプ、投与経路、流通チャネル、地域に区分されます。治療タイプ別では、抗ウイルス薬、抗炎症薬、その他に分類されます。投与経路では、経口剤と外用剤に分類されます。流通経路では、病院薬局、ドラッグストア・小売薬局、オンラインプロバイダに分類されます。地域別では、北米、欧州、アジア太平洋、LAMEAで分析されています。

ステークホルダーにとっての主なメリット
- 本レポートは、世界の帯状疱疹治療市場における現在および新興の市場動向と力学を幅広く分析し、有力な機会を特定するものです。
- 本調査では、世界市場の競争環境を提示し、地域ごとの競争環境を予測します。
- 市場の成長を促進および制限する要因の包括的な分析を提供しています。
- 市場動向とダイナミクスを理解するために、地域別・国別の分析が提供されています。

主要な市場セグメント
#治療タイプ別
## 抗ウイルス剤
## 抗炎症薬
## その他
#投与経路別
## 経口
## 外用
#流通経路別
## 病院薬局
## ドラッグストア・小売店
#オンラインプロバイダー
#地域別
o ##North America
###米国
###カナダ
###メキシコ
o ##ヨーロッパ
###ドイツ
###フランス
###イギリス
###イタリア
###スペイン
###その他のヨーロッパ
o ##アジア・パシフィック
###オーストラリア
###日本
###中国
###インド
###韓国
###その他のアジア太平洋地域
o ##LAMEA
###ブラジル
###サウジアラビア
###南アフリカ

#主要な市場関係者
##Abbott Laboratory
#バウシュヘルス
##Cipla Inc.
##キャンバー・ファーマシューティカルズ
##GlaxoSmithKline plc
##Merck
#ノバルティスAG
#ファイザー株式会社
##Eli Lilly and Co.
##Teva Pharmaceutical Industries Ltd##その他のLAMEA地域

ページTOPに戻る

CHAPTER 1:INTRODUCTION

1.1.Report description
1.2.Key benefits for stakeholders
1.3.Key market segments

1.3.1.List of key players profiled in the report

1.4.Research methodology

1.4.1.Secondary research
1.4.2.Primary research
1.4.3.Analyst tools and models

CHAPTER 2:EXECUTIVE SUMMARY

2.1.Key findings of the study
2.2.CXO perspective

CHAPTER 3:MARKET LANDSCAPE

3.1.Market definition and scope
3.2.Key findings

3.2.1.Top investment pockets

3.3.Porter’s five force analysis
3.4.Top player positioning, 2020
3.5.Market dynamics

3.5.1.Driver

3.5.1.1.Increase in geriatric population, coupled with rise in incidences of herpes zoster

3.5.2.Restraint

3.5.2.1.Dearth of skilled professionals

3.5.3.Opportunities

3.5.3.1.R&D investments by pharmaceutical companies

3.5.4.Impact analysis

3.6.COVID-19 Impact Analysis on Herpes Zoster Treatment Market

CHAPTER 4:HERPES ZOSTER TREATMENT MARKET, BY TREATMENT TYPE

4.1.Overview

4.1.1.Market size and forecast

4.2.Antiviral medications

4.2.1.Key market trends, growth factors, and opportunities
4.2.2.Market size and forecast, by region
4.2.3.Market analysis, by country

4.3.Anti-inflammatory medications

4.3.1.Key market trends, growth factors, and opportunities
4.3.2.Market size and forecast
4.3.3.Market analysis, by country

4.4.Others

4.4.1.Key market trends, growth factors, and opportunities
4.4.2.Market size and forecast
4.4.3.Market analysis, by country

CHAPTER 5:HERPES ZOSTER TREATMENT MARKET, BY ROUTE OF ADMINISTRATION

5.1.Overview

5.1.1.Market size and forecast, by region

5.2.Oral

5.2.1.Market size and forecast, by region
5.2.2.Market analysis, by country

5.3.Topical

5.3.1.Market size and forecast, by region
5.3.2.Market analysis, by country

CHAPTER 6:HERPES ZOSTER TREATMENT MARKET, BY DISTRIBUTION CHANNEL

6.1.Overview

6.1.1.Market size and forecast

6.2.Hospital pharmacies

6.2.1.Market size and forecast, by region
6.2.2.Market analysis, by country

6.3.Drug stores & retail pharmacies

6.3.1.Market size and forecast, by region
6.3.2.Market analysis, by country

6.4.Online providers

6.4.1.Market size and forecast, by region
6.4.2.Market analysis, by country

CHAPTER 7:HERPES ZOSTER TREATMENT MARKET, BY REGION

7.1.Overview

7.1.1.Market size and forecast

7.2.North America

7.2.1.Key market trends, growth factors, and opportunities
7.2.3.North America market size and forecast, By Route of administration
7.2.4.North America market size and forecast, by Distribution Channel

7.2.5.1.U.S

7.2.5.1.1.U.S. Herpes Zoster Treatment market, by Treatment Type
7.2.5.1.2.U.S. Herpes Zoster Treatment market, By Route of administration
7.2.5.1.3.U.S. Herpes Zoster Treatment market, by Distribution Channel

7.2.5.2.Canada

7.2.5.2.1.Canada Herpes Zoster Treatment market, by Treatment Type
7.2.5.2.2.Canada Herpes Zoster Treatment market, By Route of administration
7.2.5.2.3.Canada Herpes Zoster Treatment market, by Distribution Channel

7.2.5.3.Mexico

7.2.5.3.1.Mexico Herpes Zoster Treatment market, by Treatment Type
7.2.5.3.2.Mexico Herpes Zoster Treatment market, By Route of administration
7.2.5.3.3.Mexico Herpes Zoster Treatment market, by Distribution Channel

7.3.Europe

7.3.1.Key market trends, growth factors, and opportunities
7.3.2.Europe market size and forecast, by Treatment Type
7.3.3.Europe market size and forecast, By Route of administration
7.3.4.Europe market size and forecast, by Distribution Channel
7.3.5.Market size and forecast, by country

7.3.5.1.Germany

7.3.5.1.1.Germany Herpes Zoster Treatment market, by Treatment Type
7.3.5.1.2.Germany Herpes Zoster Treatment market, By Route of administration
7.3.5.1.3.Germany Herpes Zoster Treatment market, by Distribution Channel

7.3.5.2.France

7.3.5.2.1.France Herpes Zoster Treatment market, by Treatment Type
7.3.5.2.2.France Herpes Zoster Treatment market, By Route of administration
7.3.5.2.3.France Herpes Zoster Treatment market, by Distribution Channel

7.3.5.3.UK

7.3.5.3.1.UK Herpes Zoster Treatment market, by Treatment Type
7.3.5.3.2.UK Herpes Zoster Treatment market, By Route of administration
7.3.5.3.3.UK Herpes Zoster Treatment market, by Distribution Channel

7.3.5.4.Italy

7.3.5.4.1.Italy Herpes Zoster Treatment market, by Treatment Type
7.3.5.4.2.Italy Herpes Zoster Treatment market, By Route of administration
7.3.5.4.3.Italy Herpes Zoster Treatment market, by Distribution Channel

7.3.5.5.Spain

7.3.5.5.1.Spain Herpes Zoster Treatment market, by Treatment Type
7.3.5.5.2.Spain Herpes Zoster Treatment market, By Route of administration
7.3.5.5.3.Spain Herpes Zoster Treatment market, by Distribution Channel

7.3.5.6.Rest of Europe

7.3.5.6.1.Rest of Europe Herpes Zoster Treatment market, by Treatment Type
7.3.5.6.2.Rest of Europe Herpes Zoster Treatment market, By Route of administration
7.3.5.6.3.Rest of Europe Herpes Zoster Treatment market, by Distribution Channel

7.4.Asia-Pacific

7.4.1.Key market trends, growth factors, and opportunities
7.4.2.Asia-Pacific market size and forecast, by Treatment Type
7.4.3.Asia-Pacific market size and forecast, By Route of administration
7.4.4.Asia-Pacific market size and forecast, by Distribution Channel
7.4.5.Market size and forecast, by country

7.4.5.1.Japan

7.4.5.1.1.Japan Herpes Zoster Treatment market, by Treatment Type
7.4.5.1.2.Japan Herpes Zoster Treatment market, By Route of administration
7.4.5.1.3.Japan Herpes Zoster Treatment market, by Distribution Channel

7.4.5.2.China

7.4.5.2.1.China Herpes Zoster Treatment market, by Treatment Type
7.4.5.2.2.China Herpes Zoster Treatment market, By Route of administration
7.4.5.2.3.China Herpes Zoster Treatment market, by Distribution Channel

7.4.5.3.Australia

7.4.5.3.1.Australia Herpes Zoster Treatment market, by Treatment Type
7.4.5.3.2.Australia Herpes Zoster Treatment market, By Route of administration
7.4.5.3.3.Australia Herpes Zoster Treatment market, by Distribution Channel

7.4.5.4.India

7.4.5.4.1.India Herpes Zoster Treatment market, by Treatment Type
7.4.5.4.2.India Herpes Zoster Treatment market, By Route of administration
7.4.5.4.3.India Herpes Zoster Treatment market, by Distribution Channel

7.4.5.5.South Korea

7.4.5.5.1.South Korea Herpes Zoster Treatment market, by Treatment Type
7.4.5.5.2.South Korea Herpes Zoster Treatment market, By Route of administration
7.4.5.5.3.South Korea Herpes Zoster Treatment market, by Distribution Channel

7.4.5.6.Rest of Asia-Pacific

7.4.5.6.1.Rest of Asia-Pacific Herpes Zoster Treatment market, by Treatment Type
7.4.5.6.2.Rest of Asia-Pacific Herpes Zoster Treatment market, By Route of administration
7.4.5.6.3.Rest of Asia-Pacific Herpes Zoster Treatment market, by Distribution Channel

7.5.LAMEA

7.5.1.Key market trends, growth factors, and opportunities
7.5.2.LAMEA market size and forecast, by Treatment Type
7.5.3.LAMEA market size and forecast, By Route of administration
7.5.4.LAMEA market size and forecast, by Distribution Channel
7.5.5.Market size and forecast, by country

7.5.5.1.Brazil

7.5.5.1.1.Brazil Herpes Zoster Treatment market, by Treatment Type
7.5.5.1.2.Brazil Herpes Zoster Treatment market, By Route of administration
7.5.5.1.3.Brazil Herpes Zoster Treatment market, by Distribution Channel

7.5.5.2.Saudi Arabia

7.5.5.2.1.Saudi Arabia Herpes Zoster Treatment market, by Treatment Type
7.5.5.2.2.Saudi Arabia Herpes Zoster Treatment market, By Route of administration
7.5.5.2.3.Saudi Arabia Herpes Zoster Treatment market, by Distribution Channel

7.5.5.3.South Africa

7.5.5.3.1.South Africa Herpes Zoster Treatment market, by Treatment Type
7.5.5.3.2.South Africa Herpes Zoster Treatment market, By Route of administration
7.5.5.3.3.South Africa Herpes Zoster Treatment market, by Distribution Channel

7.5.5.4.Rest of LAMEA

7.5.5.4.1.Rest of LAMEA herpes zoster treatment market, by Treatment Type
7.5.5.4.2.Rest of LAMEA Herpes Zoster Treatment market, By Route of administration
7.5.5.4.3.Rest of LAMEA Herpes Zoster Treatment market, by Distribution Channel

CHAPTER 8:COMPANY PROFILES

8.1.ABBOTT LABORATORIES.

8.1.1.Company overview
8.1.2.Operating business segment
8.1.3.Product portfolio
8.1.4.Business performance

8.2.BAUSCH HEALTH COMPANIES INC.

8.2.1.Company overview
8.2.2.Company snapshot
8.2.3.Operating business segments
8.2.4.Product portfolio
8.2.5.Business performance

8.3.CAMBER PHARMACEUTICALS

8.3.1.Company overview
8.3.2.Company snapshot
8.3.3.Operating business segments
8.3.4.Product portfolio
8.3.5.Key strategic moves and developments

8.4.CIPLA INC.

8.4.1.Company overview
8.4.2.Company snapshot
8.4.3.Operating business segments
8.4.4.Product portfolio
8.4.5.Business performance.

8.5.ELI LILLY AND COMPANY

8.5.1.Company overview
8.5.2.Company snapshot
8.5.3.Operating business segments
8.5.4.Product portfolio
8.5.5.Business performance

8.6.GLAXOSMITHKLINE PLC (GSK)

8.6.1.Company overview
8.6.2.Company snapshot
8.6.3.Operating business segments
8.6.4.Product portfolio
8.6.5.Business performance.

8.7.MERCK & COMPANY INC.

8.7.1.Company overview
8.7.2.Company snapshot
8.7.3.Operating business segments
8.7.4.Product portfolio
8.7.5.Business performance

8.8.NOVARTIS INTERNATIONAL AG (SANDOZ)

8.8.1.Company overview
8.8.2.Company snapshot
8.8.3.Operating business segments
8.8.4.Product portfolio
8.8.5.Business performance

8.9.PFIZER INC.

8.9.1.Company overview
8.9.2.Company snapshot
8.9.3.Operating business segments
8.9.4.Product portfolio
8.9.5.Business performance

8.10.TEVA PHARMACEUTICALS

8.10.1.Company overview
8.10.2.Company snapshot
8.10.3.Operating business segments
8.10.4.Product portfolio
8.10.5.Business performance

List of Tables

LIST OF TABLES

TABLE 01.GLOBAL HERPES ZOSTER TREATMENT MARKET, BY TREATMENT TYPE, 2020–2030 ($MILLION)
TABLE 02.ANTIVIRAL MEDICATION HERPES ZOSTER TREATMENT MARKET, BY REGION, 2020–2030 ($MILLION)
TABLE 03.ANTI-INFLAMMATORY MEDICATIONS HERPES ZOSTER TREATMENT MARKET, BY REGION, 2020–2030 ($MILLION)
TABLE 04.OTHERS HERPES ZOSTER TREATMENT MARKET, BY REGION, 2020–2030 ($MILLION)
TABLE 05.ROUTE OF ADMINISTRATION HERPES ZOSTER TREATMENT MARKET, BY REGION, 2020–2030 ($MILLION)
TABLE 06.ORAL HERPES ZOSTER TREATMENT MARKET, BY REGION, 2020–2030 ($MILLION)
TABLE 07.TOPICAL HERPES ZOSTER TREATMENT MARKET, BY REGION, 2020–2030 ($MILLION)
TABLE 08.GLOBAL HERPES ZOSTER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2020–2030 ($MILLION)
TABLE 09.HOSPITAL PHARMACIES HERPES ZOSTER TREATMENT MARKET, BY REGION, 2020–2030 ($MILLION)
TABLE 10.DRUG STORES & RETAIL PHARMACIES HERPES ZOSTER TREATMENT MARKET, BY REGION, 2020-2030 ($MILLION)
TABLE 11.ONLINE PROVIDERS DISTRIBUTION CHANNELS HERPES ZOSTER TREATMENT MARKET, BY REGION, 2020-2030 ($MILLION)
TABLE 12.HERPES ZOSTER TREATMENT MARKET, BY REGION, 2020–2030 ($MILLION)
TABLE 14.NORTH AMERICA HERPES ZOSTER TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020–2030 ($MILLION)
TABLE 15.NORTH AMERICA HERPES ZOSTER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2020–2030 ($MILLION)
TABLE 17.U.S. HERPES ZOSTER TREATMENT MARKET, BY TREATMENT TYPE, 2020–2030 ($MILLION)
TABLE 18.U.S. HERPES ZOSTER TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020–2030 ($MILLION)
TABLE 19.RETAIL PHARMACIES AND HOSPITAL PHARMACIES SEGMENT COLLECTIVELY U.S. HERPES ZOSTER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2020–2030 ($MILLION)
TABLE 20.CANADA HERPES ZOSTER TREATMENT MARKET, BY TREATMENT TYPE, 2020–2030 ($MILLION)
TABLE 21.CANADA HERPES ZOSTER TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020–2030 ($MILLION)
TABLE 22.CANADA HERPES ZOSTER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2020–2030 ($MILLION)
TABLE 23.MEXICO HERPES ZOSTER TREATMENT MARKET, BY TREATMENT TYPE, 2020–2030 ($MILLION)
TABLE 24.MEXICO HERPES ZOSTER TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020–2030 ($MILLION)
TABLE 25.MEXICO HERPES ZOSTER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2020–2030 ($MILLION)
TABLE 26.EUROPE HERPES ZOSTER TREATMENT MARKET, BY TREATMENT TYPE, 2020–2030 ($MILLION)
TABLE 27.EUROPE HERPES ZOSTER TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020–2030 ($MILLION)
TABLE 28.EUROPE HERPES ZOSTER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2020–2030 ($MILLION)
TABLE 29.EUROPE HERPES ZOSTER TREATMENT MARKET, BY COUNTRY, 2020–2030 ($MILLION)
TABLE 30.GERMANY HERPES ZOSTER TREATMENT MARKET, BY TREATMENT TYPE, 2020–2030 ($MILLION)
TABLE 31.GERMANY HERPES ZOSTER TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020–2030 ($MILLION)
TABLE 32.GERMANY HERPES ZOSTER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2020–2030 ($MILLION)
TABLE 33.FRANCE HERPES ZOSTER TREATMENT MARKET, BY TREATMENT TYPE, 2020–2030 ($MILLION)
TABLE 34.FRANCE HERPES ZOSTER TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020–2030 ($MILLION)
TABLE 35.FRANCE HERPES ZOSTER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2020–2030 ($MILLION)
TABLE 36.UK HERPES ZOSTER TREATMENT MARKET, BY TREATMENT TYPE, 2020–2030 ($MILLION)
TABLE 37.UK HERPES ZOSTER TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020–2030 ($MILLION)
TABLE 38.UK HERPES ZOSTER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2020–2030 ($MILLION)
TABLE 39.ITALY HERPES ZOSTER TREATMENT MARKET, BY TREATMENT TYPE, 2020–2030 ($MILLION)
TABLE 40.ITALY HERPES ZOSTER TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020–2030 ($MILLION)
TABLE 41.ITALY HERPES ZOSTER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2020–2030 ($MILLION)
TABLE 42.SPAIN HERPES ZOSTER TREATMENT MARKET, BY TREATMENT TYPE, 2020–2030 ($MILLION)
TABLE 43.SPAIN HERPES ZOSTER TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020–2030 ($MILLION)
TABLE 44.SPAIN HERPES ZOSTER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2020–2030 ($MILLION)
TABLE 45.REST OF EUROPE HERPES ZOSTER TREATMENT MARKET, BY TREATMENT TYPE, 2020–2030 ($MILLION)
TABLE 46.REST OF EUROPE HERPES ZOSTER TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020–2030 ($MILLION)
TABLE 47.REST OF EUROPE HERPES ZOSTER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2020–2030 ($MILLION)
TABLE 48.ASIA-PACIFIC HERPES ZOSTER TREATMENT MARKET, BY TREATMENT TYPE, 2020–2030 ($MILLION)
TABLE 49.ASIA-PACIFIC HERPES ZOSTER TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020–2030 ($MILLION)
TABLE 50.ASIA-PACIFIC HERPES ZOSTER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2020–2030 ($MILLION)
TABLE 51.ASIA-PACIFIC HERPES ZOSTER TREATMENT MARKET, BY COUNTRY, 2020–2030 ($MILLION)
TABLE 52.JAPAN HERPES ZOSTER TREATMENT MARKET, BY TREATMENT TYPE, 2020–2030 ($MILLION)
TABLE 53.JAPAN HERPES ZOSTER TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020–2030 ($MILLION)
TABLE 54.JAPAN HERPES ZOSTER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2020–2030 ($MILLION)
TABLE 55.CHINA HERPES ZOSTER TREATMENT MARKET, BY TREATMENT TYPE, 2020–2030 ($MILLION)
TABLE 56.CHINA HERPES ZOSTER TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020–2030 ($MILLION)
TABLE 57.CHINA HERPES ZOSTER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2020–2030 ($MILLION)
TABLE 58.AUSTRALIA HERPES ZOSTER TREATMENT MARKET, BY TREATMENT TYPE, 2020–2030 ($MILLION)
TABLE 59.AUSTRALIA HERPES ZOSTER TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020–2030 ($MILLION)
TABLE 60.AUSTRALIA HERPES ZOSTER TREATMENT MARKET, BY TREATMENT TYPE, 2020–2030 ($MILLION)
TABLE 61.INDIA HERPES ZOSTER TREATMENT MARKET, BY TREATMENT TYPE, 2020–2030 ($MILLION)
TABLE 62.INDIA HERPES ZOSTER TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020–2030 ($MILLION)
TABLE 63.INDIA HERPES ZOSTER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2020–2030 ($MILLION)
TABLE 64.SOUTH KOREA HERPES ZOSTER TREATMENT MARKET, BY TREATMENT TYPE, 2020–2030 ($MILLION)
TABLE 65.SOUTH KOREA HERPES ZOSTER TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020–2030 ($MILLION)
TABLE 66.SOUTH KOREA HERPES ZOSTER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2020–2030 ($MILLION)
TABLE 67.REST OF ASIA-PACIFIC HERPES ZOSTER TREATMENT MARKET, BY TREATMENT TYPE, 2020–2030 ($MILLION)
TABLE 68.REST OF ASIA-PACIFIC HERPES ZOSTER TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020–2030 ($MILLION)
TABLE 69.REST OF ASIA-PACIFIC HERPES ZOSTER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2020–2030 ($MILLION)
TABLE 70.LAMEA HERPES ZOSTER TREATMENT MARKET, BY TREATMENT TYPE, 2020–2030 ($MILLION)
TABLE 71.LAMEA HERPES ZOSTER TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020–2030 ($MILLION)
TABLE 72.LAMEA HERPES ZOSTER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2020–2030 ($MILLION)
TABLE 73.LAMEA HERPES ZOSTER TREATMENT MARKET, BY COUNTRY, 2020–2030 ($MILLION)
TABLE 74.BRAZIL HERPES ZOSTER TREATMENT MARKET, BY TREATMENT TYPE, 2020–2030 ($MILLION)
TABLE 75.BRAZIL HERPES ZOSTER TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020–2030 ($MILLION)
TABLE 76.BRAZIL HERPES ZOSTER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2020–2030 ($MILLION)
TABLE 77.SAUDI ARABIA HERPES ZOSTER TREATMENT MARKET, BY TREATMENT TYPE, 2020–2030 ($MILLION)
TABLE 78.SAUDI ARABIA HERPES ZOSTER TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020–2030 ($MILLION)
TABLE 79.SAUDI ARABIA HERPES ZOSTER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2020–2030 ($MILLION)
TABLE 80.SOUTH AFRICA HERPES ZOSTER TREATMENT MARKET, BY TREATMENT TYPE, 2020–2030 ($MILLION)
TABLE 81.SOUTH AFRICA HERPES ZOSTER TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020–2030 ($MILLION)
TABLE 82.SOUTH AFRICA HERPES ZOSTER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2020–2030 ($MILLION)
TABLE 83.REST OF LAMEA HERPES ZOSTER TREATMENT MARKET, BY TREATMENT TYPE, 2020–2030 ($MILLION)
TABLE 84.REST OF LAMEA HERPES ZOSTER TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020–2030 ($MILLION)
TABLE 85.REST OF LAMEA HERPES ZOSTER TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2020–2030 ($MILLION)
TABLE 86.ABBOTT: COMPANY SNAPSHOT
TABLE 87.ABBOTT: OPERATING SEGMENT
TABLE 88.ABBOTT: PRODUCT PORTFOLIO
TABLE 89.BAUSCH: COMPANY SNAPSHOT
TABLE 90.BAUSCH: OPERATING SEGMENTS
TABLE 91.BAUSCH: PRODUCT PORTFOLIO
TABLE 92.CAMBER: COMPANY SNAPSHOT
TABLE 93.CAMBER: OPERATING SEGMENTS
TABLE 94.CAMBER: PRODUCT PORTFOLIO
TABLE 95.CAMBER: KEY STRATEGIC MOVES AND DEVELOPMENTS
TABLE 96.CIPLA: COMPANY SNAPSHOT
TABLE 97.CIPLA: OPERATING SEGMENTS
TABLE 98.CIPLA: PRODUCT PORTFOLIO
TABLE 99.LILLY: COMPANY SNAPSHOT
TABLE 100.LILLY: OPERATING SEGMENTS
TABLE 101.LILLY: PRODUCT PORTFOLIO
TABLE 102.GSK: COMPANY SNAPSHOT
TABLE 103.GSK: OPERATING SEGMENTS
TABLE 104.GSK: PRODUCT PORTFOLIO
TABLE 105.MERCK: COMPANY SNAPSHOT
TABLE 106.MERCK: OPERATING SEGMENTS
TABLE 107.MERCK: PRODUCT PORTFOLIO
TABLE 108.NOVARTIS AG: COMPANY SNAPSHOT
TABLE 109.NOVARTIS: OPERATING SEGMENTS
TABLE 110.NOVARTIS AG: PRODUCT PORTFOLIO
TABLE 111.PFIZER: COMPANY SNAPSHOT
TABLE 112.PFIZER: OPERATING BUSINESS SEGMENTS
TABLE 113.PFIZER: PRODUCT PORTFOLIO
TABLE 114.TEVA: COMPANY SNAPSHOT
TABLE 115.TEVA: OPERATING SEGMENTS
TABLE 116.TEVA: PRODUCT PORTFOLIO

List of Figures

LIST OF FIGURES

FIGURE 01.GLOBAL HERPES ZOSTER TREATMENT MARKET SEGMENTATION
FIGURE 02.TOP INVESTMENT POCKETS
FIGURE 03.HIGH BARGAINING POWER OF SUPPLIERS
FIGURE 04.MODERATE BARGAINING POWER OF BUYERS
FIGURE 05.HIGH THREAT OF SUBSTITUTES
FIGURE 06.MODERATE THREAT OF NEW ENTRANTS
FIGURE 07.HIGH INTENSITY OF RIVALRY
FIGURE 08.TOP PLAYER POSITIONING, 2020
FIGURE 09.IMPACT ANALYSIS
FIGURE 10.COMPARATIVE ANALYSIS OF ANTIVIRAL MEDICATION HERPES ZOSTER TREATMENT MARKET, BY COUNTRY, 2020-2030 ($MILLION)
FIGURE 11.COMPARATIVE ANALYSIS OF ANTI-INFLAMMATORY MEDICATIONS HERPES ZOSTER TREATMENT MARKET, BY COUNTRY, 2020-2030 ($MILLION)
FIGURE 12.COMPARATIVE ANALYSIS OF OTHERS HERPES ZOSTER TREATMENT MARKET, BY COUNTRY, 2020-2030 ($MILLION)
FIGURE 13.COMPARATIVE ANALYSIS OF ORAL HERPES ZOSTER TREATMENT MARKET, BY COUNTRY, 2020–2030 ($MILLION)
FIGURE 14.COMPARATIVE ANALYSIS OF TOPICAL HERPES ZOSTER TREATMENT MARKET, BY COUNTRY, 2020–2030 ($MILLION)
FIGURE 15.COMPARATIVE ANALYSIS OF HOSPITAL PHARMACIES HERPES ZOSTER TREATMENT MARKET, BY COUNTRY, 2020-2030 ($MILLION)
FIGURE 16.COMPARATIVE ANALYSIS OF DRUG STORES & RETAIL PHARMACIES HERPES ZOSTER TREATMENT MARKET, BY COUNTRY, 2020-2030 ($MILLION)
FIGURE 17.COMPARATIVE ANALYSIS OF ONLINE PROVIDERS DISTRIBUTION CHANNELS HERPES ZOSTER TREATMENT MARKET, BY COUNTRY, 2020-2030 ($MILLION)
FIGURE 18.ABBOTT: NET SALES, 2020 ($MILLION)
FIGURE 19.ABBOTT: REVENUE SHARE PER SEGMENT 2020(%)
FIGURE 20.ABBOTT: REVENUE SHARE, BY REGION 2020(%)
FIGURE 21.BAUSCH: NET SALES, 2018–2020 ($MILLION)
FIGURE 22.BAUSCH: REVENUE SHARE, BY SEGMENT, 2020 (%)
FIGURE 23.BAUSCH: REVENUE SHARE, BY REGION, 2020 (%)
FIGURE 24.CIPLA: NET SALES, 2018–2020 ($MILLION)
FIGURE 25.CIPLA: REVENUE SHARE, BY SEGMENT, 2020 (%)
FIGURE 26.LILLY: NET SALES, 2018–2020 ($MILLION)
FIGURE 27.LILLY: REVENUE SHARE, BY SEGMENT, 2020 (%)
FIGURE 28.LILLY: REVENUE SHARE, BY REGION, 2020(%)
FIGURE 29.GSK: NET SALES, 2018–2020 ($MILLION)
FIGURE 30.GSK: REVENUE SHARE, BY SEGMENT, 2020 (%)
FIGURE 31.GSK: REVENUE SHARE, BY REGION, 2020 (%)
FIGURE 32.MERCK: NET SALES, 2018–2020 ($MILLION)
FIGURE 33.MERCK: REVENUE SHARE, BY PRODUCT, 2020 (%)
FIGURE 34.MERCK: REVENUE SHARE, BY REGION, 2020 (%)
FIGURE 35.NOVARTIS: NET SALES, 2018–2020 ($MILLION)
FIGURE 36.NOVARTIS: REVENUE SHARE, BY SEGMENT, 2020 (%)
FIGURE 37.NOVARTIS: REVENUE SHARE, BY REGION, 2020 (%)
FIGURE 38.PFIZER: NET SALES, 2018–2020 ($MILLION)
FIGURE 39.PFIZER: REVENUE SHARE, BY REGION, 2020 (%)
FIGURE 40.TEVA.: REVENUE, 2018–2020 ($MILLION)
FIGURE 41.TEVA: REVENUE SHARE, BY REGION, 2020 (%)

ページTOPに戻る

Table of Contents

Summary

The global herpes zoster treatment market was valued at $217.09 million in 2020, and is projected to reach $303.42 million by 2030, registering a CAGR of 3.4% from 2021 to 2030.
Herpes zoster (shingles) is a viral infection, caused due to the varicella-zoster virus. It is usually a painful rash on the skin that causes flickering, torment, and itchy blisters on the back, chest, and face and spreads to The rest of the body. Symptoms typically start with pain along the affected dermatome, which is followed by an enlarged vesicular eruption in 2-3 days. Symptoms include lymph nodes, fever, chills, and headache, itching, raised dots on skin and redness in that area, stabbing or shooting pain, tingling, or burning feeling in or under the skin, and upset stomach. Anyone who gets herpes zoster has a history of chickenpox, often decades earlier. These two conditions come from the same virus, called varicella zoster. In addition, individuals with herpes zoster can infect another person who never had chicken pox, yet the individual will foster chicken pox and not herpes zoster. Herpes zoster is pervasive in older adults as they have weak immune system. Individuals going through radiation treatment or chemotherapy have weakened immune system and are more inclined to get herpes zoster sickness.
In addition, PCR can be used to detect VZV DNA rapidly and sensitively, and is now widely available. After the analysis of herpes zoster, drug is given for treatment, which incorporates oral medications and antibodies. Antihistamines, desensitizing creams, gels, or fixes are given to lessen the agony. Vaccines are given to more established individuals who have a higher risk of acquiring herpes zoster.
Herpes zoster occurs due to reactivation of varicella zoster virus in older age and the incidences of herpes zoster is higher in geriatric population compared to adults and children. For instance, in 2021, the U.S. reported that the risk of herpes zoster increases with age. It has been expected that the incidence of herpes zoster in the U.S. will increase with increasing older age population.
Moreover, increase in geriatric population, coupled with rising incidences of herpes zoster also contribute toward growth of the market. However, dearth of skilled professionals is expected to hinder growth of the market. Conversely, increase in drug development provides lucrative growth opportunities to the market.
The global herpes zoster treatment market is segmented into treatment type, route of administration, distribution channel, and region. By treatment type, the market is categorized into antiviral medications, anti-inflammatory medications, and others. On the basis of route of administration, it is segregated into oral and topical. Depending on distribution channel, it is classified into hospital pharmacies, drug stores & retail pharmacies, and online providers. Region wise, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

KEY BENEFITS FOR STAKEHOLDERS
• This report provides an extensive analysis of the current and emerging market trends and dynamics in the global herpes zoster treatment market to identify the prevailing opportunities.
• This study presents the competitive landscape of the global market to predict the competitive environment across geographies.
• Comprehensive analysis of factors that drive and restrict the market growth is provided.
• Region- & country-wise analysis is provided to understand the market trends and dynamics.

KEY MARKET SEGMENTS
#By Treatment Type
## Antiviral Medications
## Anti-inflammatory Medications
## Others
#By Route of Administration
## Oral
## Topical
#By Distribution Channel
## Hospital Pharmacies
## Drug Stores & Retail Pharmacies
## Online Providers
#By Region
o ##North America
 ###U.S.
 ###Canada
 ###Mexico
o ##Europe
 ###Germany
 ###France
 ###UK
 ###Italy
 ###Spain
 ###Rest of Europe
o ##Asia-Pacific
 ###Australia
 ###Japan
 ###China
 ###India
 ###South Korea
 ###Rest of Asia-Pacific
o ##LAMEA
 ###Brazil
 ###Saudi Arabia
 ###South Africa

#KEY MARKET PLAYERS
##Abbott Laboratory
##Bausch Health
##Cipla Inc.
##Camber Pharmaceuticals.
##GlaxoSmithKline plc
##Merck
##Novartis AG,
##Pfizer Inc.,
##Eli Lilly and Co.
##Teva Pharmaceutical Industries Ltd###Rest of LAMEA

ページTOPに戻る

ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。

webからのご注文・お問合せはこちらのフォームから承ります

本レポートと同分野（ネットワーク）の最新刊レポート

Allied Market Research社のその他分野での最新刊レポート

本レポートと同じKEY WORD（channel）の最新刊レポート

よくあるご質問

Allied Market Research社はどのような調査会社ですか?

アライドマーケットリサーチ（Allied Market Research）は世界の多様な市場に関する戦略や将来推計、成長/衰退予測、機会分析、消費者調査などを行い、市場調査レポートを積極的に出版しています。もっと見る

調査レポートの納品までの日数はどの程度ですか?

在庫のあるものは速納となりますが、平均的には 3-４日と見て下さい。
但し、一部の調査レポートでは、発注を受けた段階で内容更新をして納品をする場合もあります。
発注をする前のお問合せをお願いします。

注文の手続きはどのようになっていますか?

1)お客様からの御問い合わせをいただきます。
2)見積書やサンプルの提示をいたします。
3)お客様指定、もしくは弊社の発注書をメール添付にて発送してください。
4)データリソース社からレポート発行元の調査会社へ納品手配します。
5) 調査会社からお客様へ納品されます。最近は、pdfにてのメール納品が大半です。

お支払方法の方法はどのようになっていますか?

納品と同時にデータリソース社よりお客様へ請求書（必要に応じて納品書も）を発送いたします。
お客様よりデータリソース社へ（通常は円払い）の御振り込みをお願いします。
請求書は、納品日の日付で発行しますので、翌月最終営業日までの当社指定口座への振込みをお願いします。振込み手数料は御社負担にてお願いします。
お客様の御支払い条件が60日以上の場合は御相談ください。
尚、初めてのお取引先や個人の場合、前払いをお願いすることもあります。ご了承のほど、お願いします。

データリソース社はどのような会社ですか?

当社は、世界各国の主要調査会社・レポート出版社と提携し、世界各国の市場調査レポートや技術動向レポートなどを日本国内の企業・公官庁及び教育研究機関に提供しております。
世界各国の「市場・技術・法規制などの」実情を調査・収集される時には、データリソース社にご相談ください。
お客様の御要望にあったデータや情報を抽出する為のレポート紹介や調査のアドバイスも致します。

サマリー

目次

Summary

Table of Contents

ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。

本レポートと同分野（ネットワーク）の最新刊レポート

Allied Market Research社のその他分野での最新刊レポート

本レポートと同じKEY WORD（channel）の最新刊レポート

よくあるご質問

Allied Market Research社はどのような調査会社ですか?

調査レポートの納品までの日数はどの程度ですか?

注文の手続きはどのようになっていますか?

お支払方法の方法はどのようになっていますか?

データリソース社はどのような会社ですか?